Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …

Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide
and has a poor prognosis. Current treatments for advanced NSCLC included traditional …

Introduction Numerous therapeutic agents specifically targeting the mesenchymal-epithelial
transition (MET) oncogene are being developed. Objective The aim of the current review …

Among hundreds of thousands of signal receptors contributing to oncogenic activation,
tumorigenesis, and metastasis, the hepatocyte growth factor (HGF) receptor–also called …

Lung cancer continues to be the most common cause of cancer-related mortality worldwide.
Recent advances in molecular diagnostics and immunotherapeutics have propelled the …

Non-small cell lung cancer (NSCLC) inevitably develops resistance to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. In 5–20% of cases, this can …

Over the years, there has been a continuous increase in clinically relevant driver mutations
in patients with non–small cell lung cancer (NSCLC). Among these, dysregulated activation …

MET receptor has emerged as a druggable target across several human cancers. Agents
targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such …